Xbrane Biopharma AB - Asset Resilience Ratio

Latest as of December 2025: 12.89%

Xbrane Biopharma AB (XBRANE) has an Asset Resilience Ratio of 12.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr86.59 Million

≈ $9.32 Million USD Cash + Short-term Investments

Total Assets

Skr671.62 Million

≈ $72.28 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2016)

This chart shows how Xbrane Biopharma AB's Asset Resilience Ratio has changed over time. Check Xbrane Biopharma AB strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Xbrane Biopharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Xbrane Biopharma AB.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr86.59 Million	12.89%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr86.59 Million	12.89%

Asset Resilience Insights

Moderate Liquidity: Xbrane Biopharma AB has 12.89% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Xbrane Biopharma AB Industry Peers by Asset Resilience Ratio

Compare Xbrane Biopharma AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Xbrane Biopharma AB (2016–2016)

The table below shows the annual Asset Resilience Ratio data for Xbrane Biopharma AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2016-12-31	26.53%	Skr31.34 Million ≈ $3.37 Million	Skr118.11 Million ≈ $12.71 Million	--

pp = percentage points

About Xbrane Biopharma AB

ST:XBRANE Sweden Biotechnology

Market Cap

$22.73 Million

Skr211.20 Million SEK

Market Cap Rank

#24653 Global

#493 in Sweden

Share Price

Skr10.25

Change (1 day)

+0.99%

52-Week Range

Skr0.24 - Skr23.30

All Time High

Skr176.00